Funds › Atle Fund Management AB
Atle Fund Management AB
13F for Q3 2026, filed Nov 12, 2026. 39 positions worth $373.4M.Managers with more than $100 million in US-listed stocks list their holdings each quarter, within 45 days of quarter end. Long positions only: no short sales or cash.
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, what are the biggest new, added, trimmed and exited positions of Atle Fund Management AB in the latest 13F quarter?
Using 13F.ai, how has Atle Fund Management AB's portfolio concentration changed over the last four quarters?
Using 13F.ai, which of Atle Fund Management AB's top holdings have also been bought by insiders recently?
Connect your AI · Plans and the 7-day free trial (card required)
Holdings, Q3 2026
Largest first. Common shares only.
| # | The fund's own figures at the end of the quarter. A report can be up to 45 days old when it is filed. Options and bonds are not counted here. | Filing | ||||
|---|---|---|---|---|---|---|
| 1 | LLY Eli Lilly and Company | 31,202 | $36.1M | 9.7% | +4.6% | 13F ↗ |
| 2 | MRK Merck & Company, Inc. | 168,987 | $24.6M | 6.6% | -10.8% | 13F ↗ |
| 3 | JNJ Johnson & Johnson | 91,387 | $24.2M | 6.5% | +7.0% | 13F ↗ |
| 4 | ABBV AbbVie Inc. | 91,294 | $23.9M | 6.4% | +41.9% | 13F ↗ |
| 5 | TMO Thermo Fisher Scientific Inc | 34,410 | $23.2M | 6.2% | +23.5% | 13F ↗ |
| 6 | BIIB Biogen Inc. | 70,955 | $16.0M | 4.3% | +13.0% | 13F ↗ |
| 7 | VRTX Vertex Pharmaceuticals Incorporated | 28,157 | $14.7M | 3.9% | +47.2% | 13F ↗ |
| 8 | RVMD Revolution Medicines, Inc. | 66,113 | $13.6M | 3.6% | -9.5% | 13F ↗ |
| 9 | ONC BeOne Medicines Ltd. · ADR | 35,679 | $13.1M | 3.5% | +1.4% | 13F ↗ |
| 10 | CVS CVS Health Corporation | 139,311 | $11.9M | 3.2% | -4.6% | 13F ↗ |
| 11 | COR Cencora, Inc. | 36,107 | $10.8M | 2.9% | +16.0% | 13F ↗ |
| 12 | BBIO BridgeBio Pharma, Inc. | 163,697 | $10.8M | 2.9% | +31.3% | 13F ↗ |
| 13 | ISRG Intuitive Surgical, Inc. | 25,648 | $10.4M | 2.8% | +4.0% | 13F ↗ |
| 14 | INSM Insmed Incorporated · Com Par $.01 | 87,469 | $10.0M | 2.7% | +49.8% | 13F ↗ |
| 15 | EW Edwards Lifesciences Corporation | 109,647 | $9.5M | 2.5% | +6.2% | 13F ↗ |
| 16 | SYK Stryker Corporation | 34,296 | $9.4M | 2.5% | +13.3% | 13F ↗ |
| 17 | INCY Incyte Corporation | 77,377 | $9.4M | 2.5% | +35.9% | 13F ↗ |
| 18 | KRYS Krystal Biotech, Inc. | 28,074 | $9.3M | 2.5% | +16.9% | 13F ↗ |
| 19 | DXCM DexCom, Inc. | 89,251 | $7.7M | 2.1% | +24.2% | 13F ↗ |
| 20 | NAMS NewAmsterdam Pharma Company N.V. | 303,824 | $7.4M | 2.0% | +22.1% | 13F ↗ |
| 21 | IRTC iRhythm Holdings, Inc. | 54,102 | $6.1M | 1.6% | Unchanged | 13F ↗ |
| 22 | GILD Gilead Sciences, Inc. | 40,461 | $6.0M | 1.6% | -12.3% | 13F ↗ |
| 23 | MIRM Mirum Pharmaceuticals, Inc. | 70,071 | $6.0M | 1.6% | -30.5% | 13F ↗ |
| 24 | CAH Cardinal Health, Inc. | 26,735 | $5.9M | 1.6% | +13.1% | 13F ↗ |
| 25 | BSX Boston Scientific Corporation | 130,622 | $5.7M | 1.5% | -10.8% | 13F ↗ |
| 26 | ALKS Alkermes plc | 136,225 | $5.5M | 1.5% | -36.1% | 13F ↗ |
| 27 | NBIX Neurocrine Biosciences, Inc. | 38,611 | $5.5M | 1.5% | -47.0% | 13F ↗ |
| 28 | TNGX Tango Therapeutics, Inc. | 184,394 | $4.6M | 1.2% | -7.1% | 13F ↗ |
| 29 | ABVX Abivax SA · ADR | 46,452 | $4.6M | 1.2% | -20.1% | 13F ↗ |
| 30 | SYRE Spyre Therapeutics, Inc. | 44,243 | $3.9M | 1.1% | -22.4% | 13F ↗ |
| 31 | ORKA Oruka Therapeutics, Inc. | 43,180 | $3.6M | 1.0% | -21.3% | 13F ↗ |
| 32 | IDYA IDEAYA Biosciences, Inc. | 93,550 | $3.6M | 1.0% | -1.0% | 13F ↗ |
| 33 | SMMT Summit Therapeutics Inc. | 184,687 | $3.1M | 0.8% | New | 13F ↗ |
| 34 | CMPS COMPASS Pathways Plc · ADR | 243,506 | $3.0M | 0.8% | New | 13F ↗ |
| 35 | IRON Disc Medicine, Inc. | 43,682 | $2.9M | 0.8% | Unchanged | 13F ↗ |
| 36 | CELC Celcuity Inc. | 29,893 | $2.4M | 0.6% | -10.3% | 13F ↗ |
| 37 | PVLA Palvella Therapeutics, Inc. | 14,924 | $2.1M | 0.6% | New | 13F ↗ |
| 38 | PYXS Pyxis Oncology, Inc. | 663,772 | $1.5M | 0.4% | -31.3% | 13F ↗ |
| 39 | MANE Veradermics, Incorporated | 10,106 | $1.2M | 0.3% | New | 13F ↗ |
Changes since Q2 2026
4 new, 18 added to, 15 trimmed, 4 exited, 2 unchanged. By estimated dollars.
New positions (4)
Added to (18)
| ABBV AbbVie Inc. | 91,294 | +41.9% | $7.1M |
| VRTX Vertex Pharmaceuticals Incorporated | 28,157 | +47.2% | $4.7M |
| TMO Thermo Fisher Scientific Inc | 34,410 | +23.5% | $4.4M |
| INSM Insmed Incorporated · Com Par $.01 | 87,469 | +49.8% | $3.3M |
| BBIO BridgeBio Pharma, Inc. | 163,697 | +31.3% | $2.6M |
| INCY Incyte Corporation | 77,377 | +35.9% | $2.5M |
| BIIB Biogen Inc. | 70,955 | +13.0% | $1.8M |
| LLY Eli Lilly and Company | 31,202 | +4.6% | $1.6M |
| JNJ Johnson & Johnson | 91,387 | +7.0% | $1.6M |
| DXCM DexCom, Inc. | 89,251 | +24.2% | $1.5M |
Trimmed (15)
| NBIX Neurocrine Biosciences, Inc. | 38,611 | -47.0% | -$4.9M |
| ALKS Alkermes plc | 136,225 | -36.1% | -$3.1M |
| MRK Merck & Company, Inc. | 168,987 | -10.8% | -$3.0M |
| MIRM Mirum Pharmaceuticals, Inc. | 70,071 | -30.5% | -$2.6M |
| RVMD Revolution Medicines, Inc. | 66,113 | -9.5% | -$1.4M |
| ABVX Abivax SA · ADR | 46,452 | -20.1% | -$1.2M |
| SYRE Spyre Therapeutics, Inc. | 44,243 | -22.4% | -$1.1M |
| ORKA Oruka Therapeutics, Inc. | 43,180 | -21.3% | -$975.0K |
| GILD Gilead Sciences, Inc. | 40,461 | -12.3% | -$846.8K |
| PYXS Pyxis Oncology, Inc. | 663,772 | -31.3% | -$705.3K |
The 10 largest of each, by estimated dollars: shares changed times the later report's price. Index tracking, splits and mergers move positions too.
Compare two quarters
Pick any two quarters: what is new, added to, trimmed or exited. Premium plan.
Reported value by quarter
Value and number of positions at the end of each quarter.
Loading…
Largest positions in earlier quarters
Pick a quarter to see what the fund's biggest positions were then.
Loading…
Ten largest positions
By value, Q3 2026.
Filings
| Filing | ||||||
|---|---|---|---|---|---|---|
| Q3 2026 | Nov 12, 2026 | 13F-HR | 39 | $373.4M | Current | SEC ↗ |
| Q2 2026 | Jul 24, 2026 | 13F-HR | 39 | $371.7M | Current | SEC ↗ |
| Q1 2026 | May 11, 2026 | 13F-HR | 39 | $309.7M | Current | SEC ↗ |
| Q4 2025 | Feb 6, 2026 | 13F-HR | 39 | $313.4M | Current | SEC ↗ |
| Q3 2025 | Nov 4, 2025 | 13F-HR | 38 | $27.0M | Current | SEC ↗ |
| Q2 2025 | Jul 14, 2025 | 13F-HR | 37 | $233.7M | Current | SEC ↗ |
| Q1 2025 | May 5, 2025 | 13F-HR | 37 | $226.5M | Current | SEC ↗ |
Most recent first, up to 80. An amendment can replace a report or add holdings to it. All 13F filings
Information, not investment advice. Values are the fund's own figures at quarter end; a report can be up to 45 days old when filed. Disclaimer